AR043395A1 - COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS - Google Patents

COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS

Info

Publication number
AR043395A1
AR043395A1 ARP040100592A ARP040100592A AR043395A1 AR 043395 A1 AR043395 A1 AR 043395A1 AR P040100592 A ARP040100592 A AR P040100592A AR P040100592 A ARP040100592 A AR P040100592A AR 043395 A1 AR043395 A1 AR 043395A1
Authority
AR
Argentina
Prior art keywords
lercanidipine
angiotensin
hypertension
blocker
receptors
Prior art date
Application number
ARP040100592A
Other languages
Spanish (es)
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of AR043395A1 publication Critical patent/AR043395A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La lercanidipina se utiliza en la preparación de un medicamento para el tratamiento de la hipertensión en combinación con la administración previa, concurrente o posterior de un bloqueante de los receptores de angiotensina II (ARB) seleccionado de olmesartán, irbesartán, valsartán, telmisartán y losartán. Se reivindican las composiciones que obtienen tanto lercanidipina como el ARB.Lercanidipine is used in the preparation of a medication for the treatment of hypertension in combination with the previous, concurrent or subsequent administration of an angiotensin II receptor blocker (ARB) selected from olmesartan, irbesartan, valsartan, telmisartan and losartan. Compositions that obtain both lercanidipine and ARB are claimed.

ARP040100592A 2003-02-28 2004-02-25 COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS AR043395A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45078203P 2003-02-28 2003-02-28
US45086403P 2003-02-28 2003-02-28

Publications (1)

Publication Number Publication Date
AR043395A1 true AR043395A1 (en) 2005-07-27

Family

ID=32930575

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100592A AR043395A1 (en) 2003-02-28 2004-02-25 COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS

Country Status (4)

Country Link
AR (1) AR043395A1 (en)
CL (1) CL2004000379A1 (en)
TW (1) TW200501953A (en)
WO (1) WO2004075892A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050922A1 (en) * 2004-11-11 2006-05-18 Lek Pharmaceuticals D.D. Process for the synthesis of tetrazoles
CN1298389C (en) * 2005-01-18 2007-02-07 广东省人民医院 Compound preparation of calcium antagonist and timishatan for reducing blood pressure and its use
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
KR101247583B1 (en) * 2006-12-08 2013-03-26 한미사이언스 주식회사 Pharmaceutical composition comprising amlodipine or a pharmaceutically acceptable salt thereof and losartan or a pharmaceutically acceptable salt thereof
DE102008059206A1 (en) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
CN102600146B (en) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
MX2015002169A (en) * 2015-02-18 2016-08-17 Invekra S A P I De C V Pharmaceutical compositions for treating hypertension, based on a novel drug combination.
MX2015002170A (en) * 2015-02-18 2016-08-17 Invekra S A P I De C V Novel pharmaceutical compositions useful for treating hypertension.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
ITMI20011726A1 (en) * 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma POLYMORPHIC FORMS OF LERCANIDIPINE HYDROCHLORIDE

Also Published As

Publication number Publication date
WO2004075892A3 (en) 2004-09-30
TW200501953A (en) 2005-01-16
WO2004075892A2 (en) 2004-09-10
CL2004000379A1 (en) 2005-01-21

Similar Documents

Publication Publication Date Title
DK1854454T3 (en) Process for the preparation of amorphous telmisartan
CY1110989T1 (en) USE OF 3- (4-AMINO-1-oxo-1,3-dihydro-isoindol-2-yl) -piperidino-2,6-dione for the treatment of human lymph nodes
CY1118017T1 (en) SURVIVING DEFICIENCY AND THE DEFICIENCY OF Vitamin D WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3
AR052052A1 (en) COMBINATION THERAPY
ECSP055840A (en) DERIVATIVES OF 4-TETRAZOLIL-4 PHENYLPIPERIDINE FOR THE TREATMENT OF PAIN
CL2007001174A1 (en) Compounds derived from 4h- [1,2,4] triazol-3-yl, which exhibit activity in metabotropic glutamate receptors; intermediary compounds; pharmaceutical composition comprising the compounds; pharmaceutical combination that includes the compounds; and use of the compounds in the preparation of medications
CL2008002521A1 (en) Substituted pyrazole derivative compounds, androgen receptor antagonist; pharmaceutical composition comprising said compounds; and use of the compound for the treatment of cancer.
NO20060900L (en) Nitrooside derivatives of Losartan, Valsartan, Candesartan, Telmisartan, Eprosartan and Olmesartan as angiotensin II receptor blockers for the treatment of cardiovascular disease
CL2007001870A1 (en) PHARMACEUTICAL COMPOSITION OF SOLID DOSAGE INCLUDING VALSARTAN, AMLODIPINA, HYDROCHLOROTIAZIDA AND PHARMACEUTICALLY ACCEPTABLE ADDITIVES; PREPARATION PROCEDURE; AND USE FOR THE TREATMENT OF HYPERTENSION, CARDIAC INSUFFICIENCY, INFARTO D
CY1115004T1 (en) PHARMACEUTICAL COMBINATIONS OF AN AGGIOTACIN RECEPTOR COMPONENTS AND A WATER INHIBITOR
ECSP088692A (en) COMPOUNDS BASED ON IMIDAZOL, COMPOSITIONS THAT INCLUDE THE SAME AND METHODS OF THEIR USE
BRPI0507887A (en) multilayer tablet
CY1114957T1 (en) TWO LAYER TRAILS CONTAINING TELEMISARTAN AND AMLODIPIN
CL2011003266A1 (en) Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
CY1112751T1 (en) METHOD OF FORMING THE PROTEIN COGNITION WITH GPR119 RECEPTORS AND SELECTED COMPOUNDS
CL2010000188A1 (en) A method for treating an infection in a subject comprising the administration of 9 - [(2,2-dimethyl-propylamino) -methyl] -minocycline or a salt thereof; pharmaceutical composition comprising said compound; and its use.
AR067347A1 (en) ANTIHELMINTIC COMBINATION
CL2007002167A1 (en) Indole derived compounds, iap antagonists; pharmaceutical composition comprising said compound; and use of the compound in the treatment of cancer.
AR043395A1 (en) COMBINATION THERAPY FOR HYPERTENSION USING LERCANIDIPINE AND A BLOCKER OF ANGIOTENSIN II RECEPTORS
CL2008001238A1 (en) Isolated anti-receptor antagonist antibody grig / pro362 / jam4 / stigma murine with deposit number atcc pat-8298; pharmaceutical composition; medical use to inhibit the complement-dependent cellulst entry mediated by crig of an intracellular pathogen (pi), or to prevent or treat an infection disease mediated by a pi
AR055755A1 (en) DERIVED FROM BENCIMIDAZOL, OBTAINING PROCESSES, PHARMACEUTICAL COMPOSITIONS AND USES.
CL2011000625A1 (en) Solid preparation comprising 2-ethoxy-1 - ((2 '- (5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) biphenyl-4-yl) methyl) -1h-benzimidazole (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl carboxylate, a ph regulating agent and a calcium antagonist compound; and methods for using and improving dissolution of the compound in the solid preparation.
PE20121131A1 (en) SOLID ORAL PHARMACEUTICAL COMPOSITION IN MONOCAPA TABLET INCLUDING IRBESARTAN AND AMLODIPINE BESYLATE
ECSP10010168A (en) BENZOTIAZOLAS AS MODULATORS OF THE GHRELINA RECEPTOR
CL2007003251A1 (en) Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure